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Vascular surgery necessitating aortic occlusion produces spinal cord ischemia, which can 
subsequently lead to paraplegia. Previous studies suggest lipid-rich central nervous system tissue 
is sensitive to amplification of ischemic injury by free radical mechanisms that lead to lipid 
peroxidation [1]. Drugs that prevent free radical production and thus lipid peroxidation offer 
promise as a way to protect the spinal cord during periods of ischemia [2]. The agents 
deferoxamine and 1,2-dimethyl-3-hydroxypyrid-4- one (L1) are postulated to inhibit iron-
catalyzed lipid peroxidation. Deferoxamine is a water-soluble iron chelator that has been shown 
to attenuate reperfusion injury in isolated rat hearts [3]. L1 is a novel lipid-soluble iron chelator 
that has been shown to effectively chelate excess iron in a study of chronic transfusional iron 
overload (i.e., -thalassaemia) [4]. Our goal was to use these two drugs to test the hypothesis that 
iron plays an important role in the pathophysiologic reactions leading to spinal cord damage 
attendant to ischemia and reperfusion. 
 
Our preliminary study was performed in two stages. We first developed a model of spinal cord 
ischemia that produced paraplegia in a majority of dogs [5]. The second phase of our study used 
the initial series of dogs as historical controls to determine if treatment with deferoxamine or L1 
would significantly improve the neurologic outcome or histopathologic damage. 
 
In the second phase of our study, 13 mongrel dogs were sequentially divided into a 
deferoxamine-treated group (n = 5) and an L1 group (n = 8). The dogs were pretreated with 
atropine sulfate 0.4 mg/kg subcutaneously and acetylpromazine (0.22 mg/kg subcutaneously) 
and were anesthetized with thiopental (9 to 13 mg/kg intravenously). After intubation, nitrous 
oxide was delivered by inhalation in a 1:2 ratio with oxygen, and anesthesia was maintained by 
repeated intravenous boluses of thiopental.  
 
A balloon catheter was inflated in the aorta just distal to the left subclavian artery to achieve 
spinal cord ischemia, and the duration of ischemia was determined by the amplitude reduction of 
the mean evoked potential signal, as it was in our initial study. The details of the evoked 
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potential stimulaton, histopathologic scoring, regional blood flow studies, and neurologic 
assessment are identical to phase 1 of the study [5]. In the first group of dogs, deferoxamine  
(25 mg/kg) was infused intravenously over a 20-minute period, starting 30 minutes before aortic 
occlusion. Another 25 mg/kg dose of deferoxamine was administered over a 20-minute period 
beginning 10 minutes before reperfusion. In the other group, L1 (25 mg/kg) was administered 
intravenously according to the same protocol. All animals received humane care in compliance 
with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of Laboratory Animals" prepared by the National 
Academy of Sciences (NIH Publication No. 80-23, revised 1978). The study was approved by 
the Purdue University Animal Care and Use Committee. 
 
The mean durations of aortic occlusion in the control, deferoxamine, and L1 groups were  
36.1  8.5, 28.6  9.2, and 32.6  11.2, respectively. The correlation between neurologic 
outcome and histopathologic damage for the three groups of dogs is summarized in Fig. 1. In the 
nonintervention group, seven of the eight dogs had moderate to severe motor deficits. In the 
deferoxamine treated group, all five dogs had significantly fewer motor deficits at 24 hours than 
the control group (p = 0.005 by Fisher's exact test) as evidenced by absence of muscle spasticity 
and no brisk withdrawal to a pinch of the interdigital web. Of the eight dogs in the L1-treated 
group, six demonstrated normal muscle tone and a brisk withdrawal to a pinch of the interdigital 
web of the hind limb. There was a significant difference in the neurologic outcome of dogs in the 
L1-treated group compared with the control group (p = 0.05 by Fisher's exact test). 
 
Comparison of histopathologic results from all three groups revealed that there was no 
significant difference in the extent of microglial cell infiltration and vacuolation of the lumbar 
gray matter. However, in contrast to the historical controls, the integrity of the neurons in both 
the deferoxamine and L1 groups appeared to be preserved. Although some swelling and 
satellitosis of the lower motor neurons were present, fewer pyknotic and necrotic neurons were 
observed. The exception to this finding was the two dogs in the L1-treated group, which had 
significant motor deficits. They were found to have severe neuronal damage characterized by 
neuronophagia and pyknosis at the level of the fourth lumbar vertebra.  
 
The initial model of spinal cord ischemia we developed produced an 88% incidence of 
paraplegia in a control group of dogs and was thus used to test different pharmacologic 
interventions. The study presented was designed to evaluate the extent to which iron plays a role 
in ischemia/reperfusion injury of the spinal cord. The preliminary results of our study suggest 
that treatment with either deferoxamine or L1 will reduce cellular and functional deficits. In 
addition, the fact that amelioration of damage was achieved with a water-soluble iron chelator 
suggests that perhaps it is less crucial that a drug cross the blood-brain barrier and more crucial 
that the iron chelator be in contact with the central nervous system microvasculature. A 
prospective, randomized, double blind study is recommended to further elucidate the 









Fig. 1. Correlation of neurologic outcome and histopathologic damage for the 
historical control, deferoxamine- and L1-treated groups of dogs. On the ordinate, the 
neurologic outcome is represented semi-quantitatively with different combinations of 
increasing neurologic deficits. For this axis, the numeric value was obtained by 
summing the muscle tone and withdrawal reflex results each on a scale of 0 to 2, where 
normal = 0, hyperreflexia/hyporeflexia and slow withdrawal reflex = 1, and 
spasticity/atonia and areflexia = 2. The maximal possible score = 4; the minimum score 
= 0. On the abscissa, the histopathologic damage at level of the fourth lumbar vertebra 
(L4) is reflected by the damage score (higher number = more severe damage), which 
was determined by our previously published criteria [5]. All dogs with a neurologic 
deficit score of 2 to 4 could not walk. Dogs with a deficit score of 0 or 1 could walk. 
Therefore, note that all but one of the dogs in the control group were paralyzed, 
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